Prelude Therapeutics Ownership
| PRLD Stock | USD 0.71 0 0.14% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 75.9 M | Current Value 75.8 M | Avarage Shares Outstanding 51.3 M | Quarterly Volatility 15.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Prelude |
Prelude Stock Ownership Analysis
About 69.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.31. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Prelude Therapeutics recorded a loss per share of 1.68. The entity had not issued any dividends in recent years. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. Prelude Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 112 people. To find out more about Prelude Therapeutics contact Krishna DVM at 302 467 1280 or learn more at https://preludetx.com.Besides selling stocks to institutional investors, Prelude Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Prelude Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Prelude Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Prelude Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 7.0% of Prelude Therapeutics are currently held by insiders. Unlike Prelude Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Prelude Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Prelude Therapeutics' insider trades
Prelude Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Prelude Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Prelude Therapeutics backward and forwards among themselves. Prelude Therapeutics' institutional investor refers to the entity that pools money to purchase Prelude Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 402.3 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 392.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 365.2 K | Two Sigma Advisers, Llc | 2024-12-31 | 300 K | State Street Corp | 2024-12-31 | 293.4 K | Two Sigma Investments Llc | 2024-12-31 | 231.8 K | Rhumbline Advisers | 2024-12-31 | 166.8 K | Td Asset Management Inc | 2024-12-31 | 160.7 K | Goldman Sachs Group Inc | 2024-12-31 | 148.3 K | Orbimed Advisors, Llc | 10.9 M | Baker Bros Advisors Lp | 2024-12-31 | 10.1 M |
Prelude Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prelude Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prelude Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prelude Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prelude Therapeutics Outstanding Bonds
Prelude Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Prelude Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Prelude bonds can be classified according to their maturity, which is the date when Prelude Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.